STV (Saudi Technology Ventures)

STV is the closest thing the Middle East has to a homegrown growth-stage venture franchise, and for healthcare and AI founders chasing GCC distribution, it is rapidly becoming the unavoidable conversation. Founded in 2018 in Riyadh by Abdulrahman Tarabzouni, a former Google executive who ran emerging markets out of Mountain View before returning to Saudi Arabia to build a regional venture franchise, STV has grown into the largest independent technology investor in MENA, with reported AUM north of $800M and, by some accounts, more than $1.4B across vehicles when including its newer fund families. The firm’s defining moment in 2024 was the launch of a dedicated $100M AI fund anchored by Google, the first vehicle of its kind in the region and a genuine signal that Saudi Arabia intends to position itself as an Arabic-language and regional-AI hub rather than passively importing Silicon Valley APIs. The first investment from that AI fund, a co-led seed round in Sawt alongside T2, telegraphed STV’s intention to build the application layer rather than chase frontier model labs. For healthcare, the touchstone investment remains STV’s leadership of Vezeeta’s $12M Series C in 2018, taking the Egyptian-founded healthcare booking and practice management platform from a regional consumer brand into a serious cross-border digital health infrastructure player serving providers across Egypt, Saudi Arabia, the UAE, Lebanon, Jordan, and Nigeria. Vezeeta remains the touchstone reference because it demonstrated three things STV cares about: an Arabic-first product, a multi-country MENA expansion that did not require translation back into English-speaking markets to scale, and a regulatory navigation story that compounds with each new geography. Beyond Vezeeta, STV’s portfolio reads as an index of MENA tech category leaders, including Tabby in BNPL, Unifonic in cloud communications, Jahez in food delivery, Careem (acquired by Uber for $3.1B in 2019), and Jasper AI on the global side, and that breadth tells founders something important: STV does not write small healthcare-only checks; it writes platform-scale checks into companies it expects to dominate a vertical across MENA. The check-size band of $5M to $25M, spanning Series A through growth, reflects that posture. STV typically leads or co-leads, runs a hands-on board engagement model, and brings a level of regional regulatory and royal-court relationship navigation that no Western fund can replicate. Saudi Arabia’s Vision 2030 is not a backdrop for STV; it is the operating thesis. The Public Investment Fund, NEOM, sehat-related Ministry of Health digital initiatives, and the Saudi Data and AI Authority (SDAIA) shape capital flows and procurement in ways that materially advantage portfolio companies STV chooses to position into government tenders, and Tarabzouni has been explicit in interviews about the firm’s role in connecting founders to those institutional buyers. Healthcare founders who fit are those building application-layer AI for Arabic-language clinical workflows, payer infrastructure for the rapidly privatizing Saudi insurance market under the CCHI reforms, telemedicine and care navigation platforms targeting the GCC’s young and increasingly insured population, and digital therapeutics that align with the Kingdom’s chronic disease and lifestyle priorities articulated in Vision 2030. Founders who do not fit include early-stage seed teams without revenue or a clear MENA wedge (STV runs a seed pocket but the bar is high and the firm increasingly behaves like a Series A and growth investor), pure biotech and devices teams (out of scope), and US healthcare companies looking for a passive strategic check rather than a true regional partnership requiring local operating presence. The right entry path is via Tarabzouni or partners directly through a regional warm intro, often from another portfolio CEO or from one of STV’s anchor LPs and government-aligned co-investors. Saudi Aramco’s Wa’ed Ventures and PIF-affiliated funds frequently co-invest with STV, so an existing conversation with one creates gravity toward the other, and a credible relationship with the Ministry of Investment or SDAIA can short-circuit several stages of diligence. In the pitch, lead with a credible localization plan for Saudi Arabia or the broader GCC, demonstrate Arabic-language product depth where applicable, and quantify your alignment with Vision 2030 healthcare KPIs in concrete commercial terms rather than slogan form; STV’s diligence team has seen every flavor of vague Vision 2030 deck and the bar for substantive operational specificity is high. The caveats: STV’s diligence is rigorous and timelines stretch by US standards (expect months, not weeks, from first meeting to term sheet at the growth end), governance expectations include regional compliance and frequent in-person presence in Riyadh, the firm strongly prefers founders willing to physically operate in or near the Kingdom as the company scales, and the commingling of strategic-government interests with commercial venture returns means founders need to be comfortable with a stakeholder map that extends beyond the cap table.